Thor Medical ASA will hold its Annual General Meeting (AGM) tomorrow at 14:00 hours CEST, located at Advokatfirmaet Selmer, Ruseløkkveien 14, 0251 Oslo. Following the AGM, CEO Alf Bjørseth will deliver a presentation providing an update of Thor Medical’s go-to-market strategy.

The company aspires to emerge as a top-tier supplier of Th-228 to the radiopharmaceutical market and is progressing well in all aspects of the value chain, including the scheduled launch of the pilot plant during the second half of 2024.

With customers advancing in clinical trials and expressing interest in volume deliveries already in 2024 and 2025, Thor Medical is looking at opportunities to fast-track commercial volumes to the market by the end of 2025, with lower volumes but also significantly reduced capex requirements compared with a full-scale industrial plant.

Investment decisions for establishing commercial scale production facilities will as previously communicated be subject to successful start-up of the pilot plant, production of customer samples and conversion of customer LOIs into sales agreements, and completion of an engineering study.

The presentation can be followed through a live webcast tomorrow at 15:00 (or latest as soon as the AGM is completed) from the following link: CEO presentation

Please find the presentation attached, which will also be uploaded to www.thormedical.no.

Disclosure regulation

This information is required to be disclosed under Section 5-12 of the Securities Trading Act.

Contacts

• Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.no

Attachments

• Download announcement as PDF.pdf
• CEO presentation AGM 2024.pdf